 |
|
|
| |
Reduced Changes in Bone Mineral Density in Chronic HBV (CHB) Patients Receiving Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF)
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Wai-Kay Seto1, Yasuhiro Asahina2, Cheng-Yuan Peng3, Carol Stanciu4, Djamal Abdurakhmanov5, John F. Flaherty6, Kyungpil Kim6, Anuj Gaggar6, G Mani Subramanian6, Fehmi Tabak7, Tuan T. Nguyen8, Henry Lik-Yuen Chan9
1Queen Mary Hospital, Hong Kong; 2Tokyo Medical and Dental University, Tokyo, Japan;
3China Medical University Hospital, Taichung, Taiwan; 4University of Medicine and Pharmacy Gr. T. Popa, Iasi, Romania; 5Sechenov First Moscow State Medical University, Moscow, Russia; 6Gilead Sciences, Inc., Foster City, CA;
7Istanbul Universitesi Cerrahpassa Tip Fakultesi Hastanesi, Istanbul, Turkey;
8Research and Education, Inc., San Diego, CA; 9Prince of Wales Hospital, Hong Kong
FDA Approved TAF [Vemlidy] for HBV - (11/15/16)
European CHMP Adopts Positive Opinion for Gilead's Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection - (11/11/16)
EASL/2016: A Phase 3 Study of Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate in Patients With HBeAg-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results.......http://www.natap.org/2016/EASL/EASL_20.htm
1. Grant PM et al. Curr Opin HIV/AIDS 2016;11:326-332; 2. Fung S et al. J Hepatol. 2016;ePub(Aug 18); 3. Agarwal K, et al. J Hepatol 2015;62:533-40; 4. Buti M et al. Lancet Gastroenterology Hepatol. 2016;1:196-206; 5. Chan HLY et al. Lancet Gastroenterology Hepatol. 2016;1:185-195.
CROI/2016: Switching tenofovir DF to tenofovir alafenamide in virologically suppressed adults....TAF/FTC Noninferior to TDF/FTC, and Safer, in Switch Study......http://www.natap.org/2016/CROI/croi_36.htm
Similar E/C/F/TAF Safety and Efficacy in Old vs Younger With Renal Impairment - Geriatric patients.......http://www.natap.org/2016/AGE/AGE_16.htm
|
| |
|
|
|
|
|
